Further hearing loss during osteoporosis treatment with etidronate.
Ototoxicity is a rare and disabling complication in bisphosphonate therapy. Here we describe two patients who encountered further hearing loss during oral etidronate treatment for osteoporosis.
Yaşil
S
S
Dokuz Eylül University, Medical Faculty, Inciralti, Izmir, Turkey.
Cömlekçi
A
A
Güneri
A
A
D000368:Aged; D012968:Etidronic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010040:Otosclerosis / Q000150:complications
D012968:Etidronic Acid